Robin Carhart-Harris | |
|---|---|
.jpg) Carhart-Harris in 2019 | |
| Born | 31 August 1980 Durham, England, UK |
| Alma mater | |
| Known for | Psychedelic therapy |
| Scientific career | |
| Fields | Psychopharmacology |
| Institutions | |
| Doctoral advisor | Sue Wilson |
| Website | Official website  |
Robin Lester Carhart-Harris (born 31 August 1980) is a British psychopharmacologist who is Ralph Metzner Distinguished Professor in the Department of Neurology at the University of California, San Francisco. Previously, he founded and was Head of the Centre for Psychedelic Research at Imperial College London.[1]
He is noted for brain imaging studies of psychedelic and psychoactive drugs such as LSD, psilocybin, MDMA, and DMT, and research into their therapeutic use in treating psychiatric disorders such as depression.[2][3][4] In 2020, The Times named him one of the world's top 31 medical scientists.[5] The following year, he was included in TIME magazine's "100 Next" list of 100 notable people "poised to make history".[6]
- ^ "Robin Carhart-Harris: Profile". The Conversation. 2 July 2014. Retrieved 17 August 2023.
- ^ Huberman, Andrew (22 May 2023). "Dr. Robin Carhart-Harris: The Science of Psychedelics for Mental Health". Huberman Lab. Retrieved 19 August 2023.
- ^ Yakowicz, Will (19 November 2021). "Inside The Race To Create A Two-Hour Psychedelic Therapy Experience". Forbes. Retrieved 19 August 2023.
- ^ Humphreys, Rachel (17 October 2021). "Ecstasy, LSD and magic mushrooms: are these drugs the future of therapy?". The Guardian. Retrieved 17 August 2023.
- ^ Franklin-Wallis, Oliver (23 May 2020). "From pandemics to cancer: the science power list". The Times. Retrieved 19 August 2023.
- ^ "TIME 100 Next: Robin Carhart-Harris". TIME. Retrieved 19 August 2023.
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search